Precision BioSciences (NASDAQ:DTIL) Releases Earnings Results, Misses Estimates By $1.11 EPS

Precision BioSciences (NASDAQ:DTIL) announced its quarterly earnings data on Wednesday. The company reported ($3.20) EPS for the quarter, missing the consensus estimate of ($2.09) by ($1.11), Zacks reports. The firm had revenue of $3.47 million for the quarter, compared to the consensus estimate of $4.28 million. Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%.

Precision BioSciences Trading Up 1.6 %

Precision BioSciences stock traded up $0.07 during trading hours on Friday, reaching $4.61. The company had a trading volume of 27,326 shares, compared to its average volume of 172,313. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. Precision BioSciences has a 12-month low of $3.61 and a 12-month high of $15.97. The company has a 50-day moving average price of $5.12 and a 200 day moving average price of $6.59. The firm has a market cap of $35.37 million, a price-to-earnings ratio of 77.60 and a beta of 1.59.

Analyst Upgrades and Downgrades

Several analysts have issued reports on DTIL shares. BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price for the company in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a report on Friday.

Insider Transactions at Precision BioSciences

In related news, insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total transaction of $49,274.73. Following the transaction, the insider now owns 87,440 shares in the company, valued at $418,837.60. The trade was a 10.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Amoroso sold 36,838 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the transaction, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at $500,096.29. The trade was a 25.60 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,243 shares of company stock worth $227,424. Insiders own 4.00% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.